Erin Walls, Partner, CBRE-NE

Erin is as close as its gets to COO for this industry leading firm. When CBRE-NE won Equity Commonwealth and its 3.4M SF property management portfolio as a client earlier this year, Erin’s team integrated it into the firm’s 35M SF PM portfolio providing a seamless transition. Erin makes sure that the gears in the back of the house run smoothly for the brokers and staff in the front of the house. She also oversees HR, marketing and research. She fell into real estate taking on a temp assignment as an office manager, which quickly became a permanent job as office manager and executive assistant to co-managing partners Kevin Doyle and Andy Hoar. Commercial real estate demands that she always be her best; she likes outperforming every day. She’s the president of the NEWiRE Education Foundation. Advice: work for an organization like CBRE/NE that’s a meritocracy; excel in your role, ask questions; get involved with your company and industry groups, cultivate relationships.

Continue reading this story with a free account

Log in or register
Related Topics: Andy Hoar , Equity Commonwealth
Sign up for more articles like this
Subscribe to Bisnow's Boston Newsletters
Related Stories

Texas Flips Blue, Putting Data Center Boom On Notice

Hynes Vows To Bring Property Tax Stability As New Cook County Assessor

Donalds Makes History With Win For Florida Governor, Voters OK Property Tax Amendment

BioMed Sells Cambridge Office At A Loss: The Boston Deal Sheet

Former Randolph Event Venue Planned For 200-Room Hotel, Theater

The Geo Group To Reopen 2,329-Bed Immigration Facility In Texas

What's At Stake For CRE In Tuesday's U.S. Midterm

From Pandemic Darling To Cautionary Tale: Pickleball Clubs Face A Reckoning After Betting Big On Retail Space

'Distress Is Finally Trading': Investors Chasing Big Discounts On Boston Office

140-Acre Attleboro Golf Course Hits Market, Pitched For Redevelopment

Foundry Robotics Leaves San Francisco For New East Bay HQ

Alexandria Sells Stakes In Megacampuses To Weather Life Sciences Downturn